Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) is associated with superior overall survival (OS) for patients with chronic lymphocytic leukemia (CLL). Alemtuzumab (A) was added to FCR (CFAR) in a phase 2 trial for high-risk untreated patients < 70 years with...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Parikh, Sameer A., Keating, Michael J., O'Brien, Susan, Wang, Xuemei, Ferrajoli, Alessandra, Faderl, Stefan, Burger, Jan, Koller, Charles, Estrov, Zeev, Badoux, Xavier, Lerner, Susan, Wierda, William G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2011
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081295/
https://ncbi.nlm.nih.gov/pubmed/21750315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-01-329177
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller